Framingham, MA, United States of America

Abraham Scaria

This inventor holds 29 USPTO granted patents and 14 published patent applications, plus 2 CIPO patents and 14 EPO patents, primarily in Gene Therapy Techniques. Top assignees: Genzyme Corporation, Bayer Healthcare LLC, Crispr Therapeutics Ag. Active years: 2000-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Abraham Scaria. Retrieved from https://idiyas.com/inventor/abraham-scaria

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 (Patent Applications = 14)

% Patents Active = 96.6

CIPO Patents = 2 (Patent Applications = 11)

EPO Patents = 14 (Patent Applications = 20)

Average Co-Inventor Count = 2.5

ph-index = 5

Forward Citations = 155(Granted Patents)

Location History:

Bridgewater, NJ (US) (2017 - 2021)
Cambridge, MA (US) (2014 - 2022)
Framingham, MA (US) (2000 - 2024)

Company Filing History:

Crispr Therapeutics Ag

patents

4. 1 out of 1

The United States of America as Represented by the

patent

5. 1 out of 3,693

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

6. 1 out of 3,050

University of Florida Research Foundation Inc.

patents

where one patent can have more than one assignee

Years Active: 2000-2025

Loading Chart...

Areas of Expertise:

Gene Therapy

AAV Vectors

Macular Degeneration

Retinitis Pigmentosa

Gene Editing

Fusion Proteins

CNS Therapy

Combination Therapies

Multimeric Constructs

Viral Vectors

Diabetes Treatment

Blood Coagulation

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12483047 - COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MACULAR DEGENERATION (2025-11-25),

2. 12344842 - Compositions and methods for treating and preventing macular degeneration (2025-07-01),

3. 12247201 - Materials and methods for treatment of autosomal dominant retinitis pigmentosa (2025-03-11),

4. 12241078 - AAV vectors for retinal and CNS gene therapy (2025-03-04),

5. 12215316 - Materials and methods for treatment of usher syndrome type 2A (2025-02-04),

6. 12173290 - Materials and methods for controlling gene editing (2024-12-24),

7. 12122998 - Materials and methods for treatment of usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP) (2024-10-22),

8. 11896651 - Gene editing of deep intronic mutations (2024-02-13),

9. 11299715 - Use of iNOS inhibitors to increase viral yield in culture (2022-04-12),

10. 11118177 - Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP) (2021-09-14),

11. 11084864 - Fusion proteins comprising PDGF and VEGF binding portions and methods of using thereof (2021-08-10),

12. 11072792 - Materials and methods for treatment of usher syndrome type 2A (2021-07-27),

13. 10995328 - Materials and methods for treatment of autosomal dominant cone-rod dystrophy (2021-05-04),

14. 10982228 - AAV vectors for retinal and CNS gene therapy (2021-04-20),

15. 10822391 - Fusion proteins and methods for inhibiting IL-17 pathways (2020-11-03),

Title: The Innovative Contributions of Abraham Scaria in Gene Therapy

Introduction: Abraham Scaria, based in Framingham, MA, has made significant contributions to the field of gene therapy, holding an impressive portfolio of 26 patents. His innovative work primarily focuses on advancing treatments for ocular and central nervous system (CNS) disorders.

Latest Patents: Among his latest patents, Scaria has developed improved recombinant adeno-associated virus (rAAV) vectors designed for enhanced gene therapy. His innovations include methods for treating ocular diseases and CNS disorders through advanced compositions of rAAV particles. One notable patent addresses the treatment of Usher Syndrome Type 2A, providing essential materials, methods, and kits for editing the USH2A gene in human cells. These inventions are pivotal for enhancing therapeutic options for patients suffering from these genetic conditions.

Career Highlights: Scaria's professional journey includes valuable experiences at prominent companies such as Genzyme Corporation and Crispr Therapeutics. His work in these organizations has contributed to groundbreaking advancements in genetic research and treatment methodologies.

Collaborations: Throughout his career, Scaria has collaborated with notable coworkers, including Samuel C. Wadsworth and Peter Pechan. These partnerships have fostered an environment of innovation and have played a crucial role in the development of his patents.

Conclusion: Abraham Scaria's contributions to gene therapy have significantly impacted the landscape of medical treatment for ocular and CNS disorders. With a robust portfolio of patents and a commitment to innovation, Scaria continues to be a key figure in advancing the potential of gene therapy solutions.

Profile summary based on public USPTO records.